The goal of the SPORE in Brain Cancer Career Development Program is to contribute knowledgeable, well-trained scientists experienced in multidisciplinary research to the personnel base essential for future studies in translational research in the causation and treatment of gliomas and other primary brain tumors. The primary objectives of the Career Development Program are, firstly, to train young investigators in translational, multidisciplinary brain tumor research; and, secondly, to redirect established investigators into that research. To meet these objectives, the SPORE will institute: (1) A stringent candidate selection system; (2) Comprehensive guidance by a mentor and other investigators at Mayo; (3) Support through a scientific mentor group comprised of investigators from any of the three Mayo sites with expertise in the area of interest; (4) Participation in the multi-disciplinary research courses contained within the curricula of current NIH-funded Training Grants at Mayo; and (5) Encouragement of collaboration with investigators within this SPORE, and with investigators within the other Brain SPOREs. Six potential research themes are described to demonstrate the depth and breadth of ongoing research that can be eligible for funding through the SPORE Career Development Program. These outlines represent important """"""""growth"""""""" areas within the Mayo SPORE in Brain Cancer and for the SPORE Program overall. Dr. Brian Patrick O'Neill, the overall PI of the Mayo SPORE in Brain Cancer will be the Director of the Career Development Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-04
Application #
7560668
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
4
Fiscal Year
2007
Total Cost
$85,085
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications